Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Summary

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Non-squamous Non-small-cell Lung Cancer
• Advanced Squamous Non-Small Cell Lung Carcinoma
• Metastatic Non-squamous Non Small Cell Lung Cancer
• Metastatic Squamous Non-Small Cell Lung Carcinoma
• Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer Stage III
• Non-small Cell Lung Cancer Stage IV
• Non-small Cell Lung Cancer Recurrent

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Genelux Corporation

Last updated on ClinicalTrials.gov

June 4, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites